Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | TRPM2 | O94759 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.48 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.48 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.48 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | LYPLA1 | O75608 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2412888 | 0.98 | KDM4E (0.96) | KDM4EHPGDMAPK1MEN1TRPM2 | |
| SCHEMBL2410144 | 0.94 | KDM4E (0.88) | KDM4EHPGDMAPK1MEN1TRPM2 | |
| SCHEMBL2409329 | 0.92 | KDM4E (0.85) | KDM4EHPGDMAPK1MEN1TRPM2 | |
| SCHEMBL12270752 | 0.90 | KDM4E (0.81) | KDM4EHPGDMAPK1MEN1TRPM2 | |
| SCHEMBL12266145 | 0.89 | CYP1A2 (0.79) | KDM4EHPGDMAPK1MEN1TRPM2 | |
| SCHEMBL14198827 | 0.89 | KDM4E (0.79) | KDM4EHPGDMAPK1MEN1TRPM2 | |
| SCHEMBL22832991 | 0.88 | MAPK1 (0.78) | KDM4EHPGDMAPK1MEN1TRPM2 | |
| SCHEMBL12266225 | 0.86 | KDM4E (0.73) | KDM4EHPGDMAPK1MEN1TRPM2 | |
| SCHEMBL1554914 | 0.86 | TSHR (0.73) | KDM4EHPGDMAPK1MEN1TRPM2 | |
| SCHEMBL12270682 | 0.86 | HPGD (0.73) | KDM4EHPGDMAPK1MEN1TRPM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 830 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367371-A1 | HYBRID BIOELECTRONIC/ENGINEERED CELL IMPLANTABLE SYSTEM FOR THERAPEUTIC AGENTS DELIVERY AND APPLICATIONS THEREOF | UNIV NORTHWESTERN (US) | 2025-12-04 | — | — | US | claimed |
| WO-2025091023-A1 | ENGINEERED CELL TRANSFECTED BY ALL-IN-ONE VECTOR FOR THERAPEUTIC AGENTS PRODUCTION AND DELIVERY AND APPLICATIONS THEREOF | NORTHWESTERN UNIVERSITY (US) | 2025-05-01 | — | — | WO | claimed |
| CN-119199000-A | Thin-layer identification of micro-emulsion for evaluating multiple particles of dyspnea Zu Pa | 新疆医科大学 | 2024-12-27 | — | — | CN | claimed |
| EP-4444283-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| WO-2024091700-A1 | HYBRID BIOELECTRONIC/ENGINEERED CELL IMPLANTABLE SYSTEM FOR THERAPEUTIC AGENTS DELIVERY AND APPLICATIONS THEREOF | NORTHWESTERN UNIVERSITY (US) | 2024-05-02 | — | — | WO | claimed |
| US-11938135-B2 | Compositions and methods for treating vascular Ehlers Danlos syndrome and associated disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-03-26 | — | — | US | claimed |
| WO-2024033113-A1 | ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN REGULATION OF SKIN PIGMENTATION | CUTANEON - SKIN & HAIR INNOVATIONS GMBH (DE) | 2024-02-15 | — | — | WO | claimed |
| EP-4321148-A1 | ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN REGULATION OF SKIN PIGMENTATION | CUTANEON - Skin & Hair Innovations GmbH (DE) | 2024-02-14 | — | — | EP | claimed |
| US-20230405136-A1 | New Combinations of Boron Compounds and Adjuvants for the Treatment of Pathophysiological Conditions and Cancer and for Muscle Regeneration | CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED, M.P. (ES) | 2023-12-21 | — | — | US | claimed |
| WO-2023196235-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2008080409-A1 | A METHOD AND KIT FOR TESTING STRESS EFFECTS IN LIVING ORGANISM | AARHUS UNIVERSITET (DK) | 2008-07-10 | — | — | WO | claimed |
| WO-2008080410-A1 | METHOD AND KIT FOR DETECTING RESISTANCE IN LIVING ORGANISMS | AARHUS UNIVERSITET (DK) | 2008-07-10 | — | — | WO | claimed |
| EP-1838678-A1 | PROCESS FOR OBTAINING CIZOLIRTINE AND ITS ENANTIOMERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-03 | — | — | EP | claimed |
| US-7109349-B2 | Process for obtaining Cizolirtine and its enantiomers | LABORATORIOS DEL DR. ESTEVE, S/A (ES) | 2006-09-19 | — | — | US | claimed |
| US-20060135788-A1 | PROCESS FOR OBTAINING CIZOLIRTINE AND ITS ENANTIOMERS | LABORATORIOS DEL DR. ESTEVE, S/A (ES) | 2006-06-22 | — | — | US | claimed |
| WO-2006063861-A1 | PROCESS FOR OBTAINING CIZOLIRTINE AND ITS ENANTIOMERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-06-22 | — | — | WO | claimed |
| EP-1671953-A1 | Process for obtaining cizolirtine and its enantiomers | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-06-21 | — | — | EP | claimed |
| WO-2006029142-A2 | METHODS AND SYSTEMS FOR TREATING ASTHMA AND OTHER RESPIRATORY DISEASES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2006-03-16 | — | — | WO | claimed |
| US-20040259842-A1 | Intracellular calcuim concentration increase inhibitors | MIKOSHIBA, KATSUHIKO (JP) | 2004-12-23 | — | — | US | claimed |
| EP-1444981-A1 | INTRACELLULAR CALCIUM CONCENTRATION INCREASE INHIBITORS | Mikoshiba, Katsuhiko (JP) | 2004-08-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259842-A1 | Intracellular calcuim concentration increase inhibitors | CAB39, BPGM, ORAI1 | KDM4E 4858/4885HPGD 1700/4885MAPK1 1089/4885 |
| US-20230405136-A1 | New Combinations of Boron Compounds and Adjuvants for the Treatment of Pathophysiological Conditions and Cancer and for Muscle Regeneration | MUSK, MBNL1, MYOF | KDM4E 4783/4885HPGD 3933/4885MAPK1 474/4885 |
| US-20060135788-A1 | PROCESS FOR OBTAINING CIZOLIRTINE AND ITS ENANTIOMERS | CYP2E1, MAP2K1, MAP2K5 | KDM4E 2413/4885HPGD 800/4885MAPK1 751/4885 |
| US-11938135-B2 | Compositions and methods for treating vascular Ehlers Danlos syndrome and associated disorders | COL2A1, COL1A1, MMP1 | KDM4E 2988/4885HPGD 633/4885MAPK1 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.